Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Organogenesis ORG -- Ignore unavailable to you. Want to Upgrade?

To: Link Lady who wrote (1162)	12/23/1998 5:37:00 PM
From: Link Lady	Read Replies (1) \| Respond to of 1223

Full article can be found here PDF file twst.com. December 23, 1998 14:32 Organogenesis CSO Alan Tuck talks to The Wall Street Transcript NEW YORK--(BUSINESS WIRE)--Dec. 23, 1998--The Wall Street Transcript has published an in-depth interview with Alan W. Tuck of Organogenesis, Inc. (AMEX:ORG), in which he talks at length about his company's future. He says, "Organogenesis was founded in 1985 and went public in 1986. The most important fact is that Organogenesis is the world's leader in tissue engineering and has developed Apligraf. Apligraf is now being sold by Novartis in the United States for the treatment of venous leg ulcers, and is the first major advance in the treatment of chronic wounds in over 100 years. Organogenesis is expanding upon this by developing other tissue-engineered and related products." He explains, "First of all, Apligraf alone offers us a major expansion opportunity working with Novartis. We will move from the one indication, venous leg ulcers, into many indications, including diabetic foot ulcers, pressure sores, cosmetic surgery, other uses for the skin. We will move from being in one major market, the United States, to worldwide usage for the product. On top of this, Organogenesis has additional products which use our expertise throughout our pipeline, and we continue to expand those opportunities for us." Looking forward, he states, "The next important Organogenesis product is called Vitrix, and that will be entering clinical trials in 1999. Vitrix builds off of many of the same processes that are used for Apligraf. It uses some of the same components as Apligraf. It is a dermal replacement product, where Apligraf is a full-skin replacement product. We will be bringing Vitrix through the clinic and into development right behind Apligraf to expand the franchise into below-surface wounds, into very deep wounds, and into surgeries that involve the oral cavity, such as periodontal surgery." To read the complete interview, go to twst.com. It requires Adobe Acrobat (tm) reader to view the document. The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. The Wall Street Transcript is a premier weekly investment publication serving serious long-term investors for over 35 years. The Transcript publishes industry roundtables and interviews with Wall Street analysts, money managers, and Company CEOs, and is read by top money managers, brokers, and individual investors. For subscription information call (800) 246 -7673. CONTACT: The Wall Street Transcript Barbara Diliberti (212) 952 - 7455 twst.com